Observational studyMedicine2025
Albumin-globulin ratio predicts 90-day functional outcomes in anterior choroidal artery territory infarction: A two-center retrospective cohort study.
Observational study in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
This study investigates the association between baseline albumin-to-globulin ratio (AGR) and 90-day functional outcomes in patients with anterior choroidal artery (AChA) territory infarction. This two-center retrospective cohort study consecutively enrolled 201 patients with AChA territory infarction admitted between September 2018 and September 2024. The primary endpoint was poor functional outcome at 90 days, defined as a modified Rankin Scale score of 3 to 6. Multivariable logistic regression models were employed to assess the association between AGR and functional outcomes, with restricted cubic spline regression used to explore potential nonlinear relationships. Among 201 patients, 72 (35.8%) experienced poor functional outcomes at 90 days. Patients with poor outcomes had significantly lower AGR levels compared to those with favorable outcomes (P < .001). In the fully adjusted model, each 0.1-unit increase in AGR was associated with a 21% reduction in the risk of poor functional outcome (odds ratio = 0.79, 95% confidence interval: 0.64-0.95, P = .015). Quartile analysis revealed a clear dose-response relationship, with the highest quartile showing an 86% reduction in the risk of poor outcome compared to the lowest quartile (odds ratio = 0.14, 95% confidence interval: 0.03-0.54, P = .007). The predictive performance of AGR (area under the curve [AUC] = 0.70) was superior to that of albumin (AUC = 0.58) or globulin (AUC = 0.67) alone. Restricted cubic spline analysis demonstrated a nonlinear relationship, with a sharp increase in the risk of poor outcomes when AGR fell below 1.4 (P-overall = .019, P-nonlinear = .045). Subgroup analyses confirmed the consistency of this association across different clinical characteristics. Lower baseline AGR is independently associated with poor 90-day functional outcomes in patients with AChA territory infarction. An AGR threshold of 1.4 may serve as a potential cutoff for clinical risk stratification. AGR represents a readily available and valuable biomarker for early risk assessment and individualized management in this specific stroke subtype.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.